CPH 0.00% 0.9¢ creso pharma limited

Ann: Options Entitlement Issue, page-17

  1. 4,263 Posts.
    lightbulb Created with Sketch. 685
    With the greatest respect, the massive dilution associated with this is terrible for shareholders. So is the fact that the business’ sales and market development are so slow that they need to keep raising capital so often. The fact it’s not underwritten doesn’t look good either. Finally, this announcements admits that one if their earliest ventures was a flop. It’s basically all very bad news in terms of signalling current/past progress. Oh, and very interesting timing too with the 4C next week. Shareholders should be extremely concerned.
    Last edited by FraserJC: 24/07/18
 
watchlist Created with Sketch. Add CPH (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.